CytomX Therapeutics (CTMX) Asset Utilization Ratio (2015 - 2026)
CytomX Therapeutics' (CTMX) quarterly Asset Utilization Ratio came in at 0.14 in Q1 2026, down 89.67% YoY from 1.35 in Q1 2025, and down 71.72% on a QoQ basis from 0.49 in Q4 2025.
CytomX Therapeutics (CTMX) Asset Utilization Ratio (2015 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 12 years of Asset Utilization Ratio data on file, last reported at 0.14 in Q1 2026.
- Quarterly Asset Utilization Ratio fell 89.67% year-over-year to 0.14 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.14 (down 89.67% YoY) and the FY2025 annual result came in at 0.56, down 34.64% from the prior year.
- Asset Utilization Ratio declined to 0.14 in Q1 2026, from 0.49 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 1.35 in Q1 2025 to a low of 0.12 in Q1 2022.
- A 5-year average of 0.54 and a median of 0.48 in 2023 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio surged 142.48% — and 2026, when it slumped 89.67%.
- Tracing CTMX's Asset Utilization Ratio over 5 years: stood at 0.22 in 2022, then jumped by 119.38% to 0.48 in 2023, then surged by 122.38% to 1.06 in 2024, then plunged by 53.78% to 0.49 in 2025, then plunged by 71.72% to 0.14 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.14 (Q1 2026), 0.49 (Q4 2025), and 0.68 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 0.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.05 |
| Mar 31, 2026 | 0.14 |
| Dec 31, 2025 | 0.49 |
| Sep 30, 2025 | 0.68 |
| Jun 30, 2025 | 1.03 |
| Mar 31, 2025 | 1.35 |
| Dec 31, 2024 | 1.06 |
| Sep 30, 2024 | 0.85 |
| Jun 30, 2024 | 0.70 |
| Mar 31, 2024 | 0.62 |
| Dec 31, 2023 | 0.48 |
| Sep 30, 2023 | 0.44 |
| Jun 30, 2023 | 0.36 |
| Mar 31, 2023 | 0.27 |
| Dec 31, 2022 | 0.22 |
| Sep 30, 2022 | 0.18 |
| Jun 30, 2022 | 0.15 |
| Mar 31, 2022 | 0.12 |
| Dec 31, 2021 | 0.11 |
| Sep 30, 2021 | 0.09 |